Ethypharm is a leading mid-size international specialty pharmaceutical company, with strong European roots, that manufactures and provides essential medicines with a focus on Central Nervous System (severe pain and addiction) and Hospital Injectables.
Discover Ethypharm at a glance
At Ethypharm, our mission is to improve patients’ lives by providing essential medicines and making a positive impact on society and the environment.
Our products are treating:
– Severe pain
– Addiction
– Critical care situations
Ethypharm is deeply engaged in the Central Nervous System and Hospital Injectable areas, where our medicines treat patients and our teams work on innovative solutions for tomorrow. Willing to grow beyond our recognised positions in the treatment of severe pain and addiction, we are constantly screening opportunities in search for those which will respond to unmet needs in our two core areas.
Ethypharm is a rapidly evolving company with a clear strategy and significant growth ambitions.
Through strategic geographical expansions and commercial team committed to achieving great results, we’re dedicated to connecting with customers and making a meaningful impact in patients’lives in every market we enter.
We are open to discussing potential partnerships.
Get to know our business development (BD) teams and come discuss with us!
Ethypharm Iberia adds Nefopam to its portfolio
Ethypharm Iberia has signed a licensing agreement with Medochemie to commercialize Nefopam HCl 20mg/2ml injectable solution in Spain. This analgesic provides an effective treatment for moderate to severe pain, addressing a real need for additional therapeutic options in the Spanish market. This new product reinforces our ambition to grow our portfolio of essential medicines in […]
Read moreRecivit® returns to Ethypharm’s portfolio in France
As of April 2025, Ethypharm has taken back the distribution in France for Recivit® (fentanyl), a treatment used in the management of severe pain. Previously distributed by Grünenthal, Recivit® is now reintegrated into the French portfolio, reinforcing Ethypharm’s longstanding experience and comprehensive approach to pain treatment. This development further demonstrates our strong commitment to bringing […]
Read more